Inflammatory Cytokines and the Pathogenesis of Periodontal Disease

Ozlem Özer Yücel
Department of Oral Pathology, Faculty of Dentistry, University of Gazi, Ankara, Turkey

Received date: March 31, 2015; Accepted date: June 26, 2015; Published date: June 30, 2015

Copyright: © 2015 Yücel OO. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Inflammatory periodontal disease is a consequence of the interaction of environmental, genetic, host and microbial factors. Destruction of tooth supporting tissues in susceptible subjects results from the shifting balance of preventive and destructive immune mechanisms against microbial pathogens [1,2].

Periodontal inflammatory response after host-bacterial interaction, progresses into a chronic stage dominated by B lymphocytes and macrophages, following intense T lymphocytes stage [3]. Transition between these stages, accumulation and differentiation of immune cells in the inflammatory site are mediated by “cytokines.” Cytokines are soluble mediators contributing many biologic processes such as hematopoiesis, wound healing, systemic and local inflammatory responses [4]. Many cell types other than immune cells like epithelial cells, gingival and periodontal ligament fibroblasts, and keratinocytes are shown to produce cytokines upon stimulation [5,6]. Cytokines show pleiotropic effects on different target cells by regulating cell activation, proliferation and function [4]. Therefore the net effect of cytokines is directing the intensity and duration of immune response which may serve as a critical determinant of tissue destruction in many inflammatory chronic diseases like rheumatoid arthritis, inflammatory osteoarthritis and periodontitis. A considerable number of studies demonstrated that the persistent host inflammatory response against bacterially derived factors results in the destruction of soft and mineralized periodontal tissues [7-10].

The complex cytokine network that mediates the immune response includes pro-inflammatory cytokines, anti-inflammatory cytokines and specific cytokine receptors [11]. As the other chronic inflammatory diseases inflammatory cytokines are considered to play an important role in the initiation, progression and the host modulation of periodontal disease [12,13]. Current knowledge supports that the immunoregulatory properties of T cell derived cytokines can improve or attenuate the progression of periodontal disease [14]. There is evidence that failure to resolve inflammatory periodontal disease may be the result of an imbalance in T helper (Th) 1, Th2 and Th17 response and pro- and anti-inflammatory cytokines [14-17]. Therefore, in this mini-review, the Th cell subsets and their cytokines which are involved in the host inflammatory response and the destruction of periodontal tissues are summarized.

The Role of Th1/Th2/Th17 Cytokines in Periodontal Disease

Histopathological studies indicate that T cells which are the source of many cytokines are the dominant cell type in periodontitis lesions [18,19]. Th cells can be subdivided into lineages on the basis of cytokine profiles, expression of transcription factors and homing receptors which are named as Th1 and Th2 lymphocytes. Recently additional subsets have been identified (Th17, Th9, Th22, Treg) the most extensively studied being the Th17 one [20].

Because Th1, Th2, Th17 and monocyte-derived cytokines in periodontal tissues and gingival crevicular fluid (GCF) are involved in periodontal inflammation, even a minimal imbalance of cytokine production may affect induction of bone and collagen destruction in periodontal disease [14-16]. As a general rule, immune responses mediated by T cells polarized into a Th1-type phenotype are characteristically cellular and pro-inflammatory; while Th2 cells are associated with humoral immunity and present anti-inflammatory properties [14].

Th1 cytokines

Th1 cells activate cellular immunity against intracellular pathogens by producing interleukin [IL]-1, IL-12, IL-2, interferon (IFN)-γ and tumor necrosis factor (TNF)-α.

IL-12, is the major cytokine which induces naive T cells in a Th1-specific manner. In humans, the major effect of IL-12 is to stimulate IFN-γ production by Th1 cells and regulate the transition from an early innate immune response to an adaptive immune response [21]. IL-12 also stimulates natural killer cells to synthesize multiple pro-inflammatory cytokines (IL-1, IFN-γ, TNF-α, IL-8) [21,22]. IL-12 was shown to mediate bone loss after P. gingivalis challenge [23]. Several other studies have attempted to determine the IL-12 profile in periodontal disease [24-26]. Although the results are contradictory, there is evidence that IL-12 plays a potential role in the progression of periodontal inflammation by inducing a Th1 response [26,27].

IL-1 is a multifactorial cytokine which is able to activate many cell types with potent inflammatory features. The wide biological effects of IL-1 result from its central role in regulation of many different genes. IL-1 affects approximately 90 genes that occur during inflammation. These include the genes which regulate cytokines, cytokine receptors, acute phase reactants, growth factors, extracellular matrix components and adhesion molecules [28]. Clinical studies have illustrated that the amount of IL-1β is much higher in GCF in periodontal pockets or in the underlying inflamed gingival tissue than at healthy sites. Furthermore, IL-1β levels are higher in active periodontitis sites than in stable sites [16,26,29]. It is known that TNF-α induces bone and extracellular matrix resorption by activating the osteoclasts in a similar way with IL-1 [30]. Monocytes and macrophages are the potent cell types producing TNF-α. The local cellular effects of TNF-α include the adhesion of polymorph nuclear leukocytes (PMNs) to endothelial cells, degradation of PMNs, activation of phagocytes and intercellular adhesion molecule (ICAM)-1 expression. The amount of TNF-α was demonstrated at high levels in gingival crevicular fluid and diseased periodontal tissues [8,16] and experimental studies have shown a central role for TNF-α in alveolar bone resorption [31,32].
Analysis of IL-1, TNF-alpha, IL-2, IFN-gamma and IL-10 mRNA levels by RT-PCR in healthy and inflamed periodontal tissues demonstrated that IL-1, TNF-alpha, IL-2, IFN-gamma levels are increased in periodontitis lesions supporting the hypothesis that Th1 cytokines are associated with periodontal tissue destruction [16].

**Th17 cytokines**

Recent studies indicate that both Th1 and Th17 can be involved in inflammatory disorders and these two cell subsets can develop concurrently [33,34]. It has been suggested that IL-1beta was essential for inducing IL-17/IFN-γ cells, the so called Th17/Th1 subset [33]. Th17 cells differentiate from CD61+ cells and CD4+ T cell precursors in the presence of IL-1beta and IL-23 [35]. The prototypical Th17 cytokine is IL-17; Th17 cells can also produce other effector cytokines with osteoclastogenic properties, such as IL-6 and IL-23. IL-17 is involved in osteoclastogenesis by inducing RANKL expression on osteoblasts [36]. The main function of IL-17 is to mediate inflammation by stimulating resident cells to secrete potent pro-inflammatory cytokines like IL-1, IL-6- IL-8 and prostaglandin E2 (PGE2) that exacerbate the inflammatory reaction and tissue destruction. Several studies demonstrated the presence of Th17 cells in chronic periodontitis lesions [37-39]. Cytokines produced and induced by Th17 cells like IL-6, IL-23 and IL-1 beta mRNA levels were reported to be elevated in lesions with periodontitis [37]. Recently, increased GCF IL-17 levels were reported in aggressive periodontitis patients [40]. Taken together, in addition to Th1/Th2 paradigm, Th17 subset has a major impact on immunoregulation of host response in periodontal tissue destruction.

**Th2 cytokines**

Th2 lymphocytes play a crucial role in humoral immunity against extracellular pathogens by producing IL-3, IL-4, IL-5, IL-6, IL-10, IL-11 and IL-13 [41].

Th2 polarization from naïve CD4 T cells is achieved by production of IL-4 [42]. Several studies have demonstrated that anti-inflammatory cytokines such as IL-4 and IL-10 can down regulate pro-inflammatory cytokine production from effector cells such as macrophages [43]. IL-10, the major anti-inflammatory cytokine demonstrates wide immunoregulatory effects by reducing IFN-gamma and IL-17 from T cells and also inhibiting bone resorption via preventing RANK-RANKL connection [44,45]. It is widely expressed in periodontal tissues and is associated with lower disease severity. Besides IL-10, another Th2 cytokine, IL-11 is supposed to have anti-inflammatory properties due to its inhibition of pro-inflammatory cytokines [46]. It has been shown that IL-11 can inhibit the production of IL-1β, TNF-α, IL-6, IL-12 p40 and nitric oxide and down regulates LPS-induced cytokines through inhibition of NF-kB expression in vitro [47,48]. In animal models, IL-11 appears to be important in controlling the development of an inflammatory response in periodontal tissues [49,50]. It was reported that the twice-weekly administration of recombinant human IL-11 in the developing periodontal disease model acted by blocking the cytokines most associated with inflammation, led to a reduction in both attachment loss and bone resorption [50]. In a study which we aimed to determine the possible role of IL-11 in periodontal pathogenesis, together with the pro-inflammatory cytokines IL-1β and IL-12, lower levels of IL-11 were detected in GCF of chronic periodontitis patients in comparison with gingivitis and healthy subjects [26]. Moreover, IL-11: IL-1β ratio became progressively lower with increasing probing depth. We suggested that IL-11 may be acting as a key mediator in preventing the progressive inflammation leading to periodontal tissue breakdown. Although a destructive role for Th2 subset via B-cell differentiation in periodontal lesions is indicated [51], Th2 cells are capable of producing multiple anti-inflammatory cytokines like IL-11, IL-10 and IL-4, which attenuate the destructive host response mediated by mostly Th1/Th17 cytokines [11].

**Concluding Remarks**

Multiple host defense mechanisms including neutrophil migration, complement activation and antibody production take action to eradicate the infection caused by periodontopathogens. Th help cytokines have a potent impact on periodontal pathogenesis by both destructive and protective perspectives. Besides their destructive effects, Th1/Th17 mediated cytokines play crucial role to generate an efficient immune response to protect the host against periodontal infection. Th2 cytokines seem to control or attenuate the up-regulation of pro-inflammatory cytokines. Further studies are required to clarify the mechanisms of Th1, Th17 and Th2 regulation in order to improve host–modulatory interventions for resolution of inflammation in periodontal diseases.

**References**

1. Kinane DF, Lappin DF (2001) Clinical, pathological and immunological aspects of periodontal disease. Acta Odontol Scand 59: 154-160.
2. Nares S (2003) The genetic relationship to periodontal disease. Periodontol 2000 32: 36-49.
3. Gemmell E, Carter CL, Seymour GJ (2001) Chemokines in human periodontal disease tissues. Clin Exp Immunol 125: 134-141.
4. Oppenheim JJ, Ruscetti, FW, Faltynek, C. Cytokines (1994) In: Stites D, Terr AJ (eds.) Basic and Clinical Immunology, pp. 105-123.
5. Baek KJ, Choi Y, Ji S (2013) Gingival fibroblasts from periodontitis patients exhibit inflammatory characteristics in vitro. Arch Oral Biol 58: 1282-1292.
6. Liang L, Yu J, Zhou W, Liu N, E LL, et al. (2014) Endothelin-1 stimulates proinflammatory cytokine expression in human periodontal ligament cells via mitogen-activated protein kinase pathway. J Periodontol 85: 618-626.
7. Graves DT, Fine D, Teng YT, Van Dyke TE, Hajishengallis G (2008) The use of rodent models to investigate host-bacteria interactions related to periodontal diseases. J Clin Periodontol 35: 89-105.
8. Graves DT, Cochran D (2003) The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. J Periodontol 74: 391-401.
9. Hori H, Liu CM, Liu BY, Lin SJ, Liao CS, et al. (2003) Interleukin-1beta, clinical parameters and matched cellular-histopathologic changes of biopsied gingival tissue from periodontitis patients. J Periodontal Res 38: 247-254.
10. Di Benedetto A, Gigante I, Colucci S, Grano M (2013) Periodontal disease: linking the primary inflammation to bone loss. Clin Dev Immunol 2013: 503754.
11. Opal SM, DePal VA (2000) Anti-inflammatory cytokines. Chest 117: 1162-1172.
12. Baccons A, Noronha S, Gómez M, Mota P, Gónzalez Moles MA, et al. (2005) Tissue destruction in periodontitis: bacteria or cytokines fault? Quintessence Int 36: 299-306.
13. Salvi GE, Lang NP (2005) Host response modulation in the management of periodontal diseases. J Clin Periodontol 6: 108-129.
14. Garlet GP (2010) Destructive and protective roles of cytokines in periodontitis: a re-appraisal from host defense and tissue destruction viewpoints. J Dent Res 89: 1349-1363.
26. Yücel OO, Berker E, Gariboğlu S, Otlu H (2008) Interleukin-11.
24. Tsai IS, Tsai CC, Ho YP, Ho KY, Wu YM, et al. (2005) Interleukin-12
17. Yücel-Lindberg T, Båge T (2013) Inflammatory mediators in the
15. Seymour GJ, Gemmell E (2001) Cytokines in periodontal disease: where
to from here? Acta Odontol Scand 59: 167-173.
16. Honda T, Domon H, Okai T, Kajita K, Amanuma R, et al. (2006) Balance of inflammatory response in stable gingivitis and progressive periodontitis lesions. Clin Exp Immunol 144: 35-40.
18. Yücel-Lindberg T, Båge T (2013) Inflammatory mediators in the
of periodontitis. Expert Rev Mol Med 15: e7.
19. Cardoso CR, Garlet GP, Moreira AP, Júnior WM, Rossi MA, et al. (2008) Characterization of CD4+CD25+ natural regulatory T cells in the inflammatory infiltrate of human chronic periodontitis. J Leukoc Biol 84: 311-318.
20. Demir T, Orbak R, Tezel A, Canakç V, Kaya H (2009) The changes in the T-lymphocyte subsets in a population of Turkish children with puberty gingivitis. Int J Paediatr Dent 19: 206-212.
21. Oates TW, Graves DT, Cochran DL (2002) Clinical, radiographic and biochemical assessment of IL-1/TNF-alpha antagonist inhibition of bone loss in experimental periodontitis. J Clin Periodontol 29: 137-143.
22. Thunell DH, Tymkiw KD, Johnson GK, Joly S, Burnell KK, et al. (2009) A multiplex immunoassay demonstrates reductions in gingival crevicular fluid cytokines following initial periodontal therapy. J Periodontal Res 45: 148-152.
23. Deleau N, Bickel M (2004) Interleukin-1 beta, interleukin-12 and the pathogenesis of inflammatory periodontal diseases. J Clin Periodontol 35: 21-41.
24. Oresto A, Gemmell E, Bickel M, Seymour GJ (2006) Interleukin-1beta, interleukin-12 and interleukin-18 levels in gingival fluid and serum of patients with gingivitis and periodontitis. Oral Microbiol Immunol 21: 256-260.
25. Yücel OO, Berker E, Gariboğlu S, Otlu H (2008) Interleukin-11, interleukin-1beta, interleukin-12 and the pathogenesis of inflammatory periodontal diseases. J Clin Periodontol 35: 365-370.
26. Thunell DH, Tymkiw KD, Johnson GK, Joly S, Burnell KK, et al. (2009) A multiplex immunoassay demonstrates reductions in gingival crevicular fluid cytokines following initial periodontal therapy. J Periodontal Res 45: 148-152.
27. Delaleu N, Bickel M (2004) Interleukin-1 beta and interleukin-18: regulation and activity in local inflammation. Periodontal 2000 2000: 42-52.
28. Engebretson SP, Grbic JT, Singer R, Lamster IB (2002) GCF IL-1beta profiles in periodontal disease. J Clin Periodontol 29: 48-53.
29. Tracey K (editor) (1997) Tumor necrosis factor. New York.
30. Oates TW, Graves DT, Cochran DL (2002) Clinical, radiographic and biochemical assessment of IL-1/TNF-alpha antagonist inhibition of bone loss in experimental periodontitis. J Clin Periodontol 29: 137-143.
31. Behl Y, Siqueira M, Ortiz J, Li J, Desta T, et al. (2008) Activation of the acquired immune response reduces coupled bone formation in response to a periodontal pathogen. J Immunol 181: 8711-8718.
32. Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, et al. (2012) Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature 484: 514-518.
33. Fouser LA, Wright JF, Dunussi-Joannopoulos K, Collins M (2008) Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev 226: 87-102.
34. Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, et al. (2008) Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med 205: 1903-1916.
35. Beklen A, Ainoia M, Hukkanen M, Gürçan C, Sorsa T, et al. (2007) MMPs, IL-1, and TNF are regulated by IL-17 in periodontitis. J Dent Res 87: 347-351.
36. Cardoso CR, Garlet GP, Crippa GE, Rosa AL, Júnior WM, et al. (2009) Evidence of the presence of T helper type 17 cells in chronic lesions of human periodontal disease. Oral Microbiol Immunol 24: 1-6.
37. Adibrad M, Deyhimi P, GanjaliKhani Hakemi M, Behfarnia P, Shahabuei M, et al. (2012) Signs of the presence of Th17 cells in chronic periodontal disease. J Periodontal Res 47: 525-531.
38. Ay ZY, Yilmaz G, Oxdem M, Koçak H, Sütçi R, et al. (2012) The gingival crevicular fluid levels of interleukin-11 and interleukin-17 in patients with aggressive periodontitis. J Periodontol 83: 1425-1431.
39. Shaker OG, Ghallab NA (2012) IL-17 and IL-11 GCF levels in aggressive and chronic periodontitis patients: relation to PCR bacterial detection. Mediators Inflamm 2012: 174764.
40. Balkwill FR, Burke F (1989) The cytokine network. Immunol Today 10: 299-304.
41. Murphy KM, Reiner SL (2002) The lineage decisions of helper T cells. Nat Rev Immunol 2: 933-944.
42. Raziuddin S, Sheikha K, Abu-Eshy S, Al-Janadi M (1998) Regulation of interleukin-4 production and cytokine-induced growth potential in peripheral T-cell non-Hodgkin's lymphomas. Br J Haematol 100: 310-316.
43. Naundorf S, Schröder M, Höflich C, Suman N, Volk HD, et al. (2009) IL-10 interferes directly with TCR-induced IFN-gamma but not IL-17 production in memory T cells. Eur J Immunol 39: 1066-1077.
44. Zhang X, Teng YT (2006) Interleukin-10 inhibits gram-negative-microbe-specific human receptor activator of NF-kappab ligand-positive CD4+Th1-cell-associated alveolar bone loss in vivo. Infect Immun 74: 4927-4931.
45. Hill PA, Tumber A, Papaoannou S, Meikle MC (1998) The cellular actions of interleukin-11 on bone resorption in vitro. Endocrinology 139: 1564-1572.
46. Trepichio WL, Wang L, Bozza M, Dorner AJ (1997) IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappab. J Immunol 159: 5661-5670.
47. Trepichio WL, Bozza M, Pedneault G, Dorner AJ (1996) Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 157: 3627-3634.
48. Bozza M, Bliss J, Maylor R, Erickson J, Donnelly L, et al. (1999) Interleukin-11 reduces T-cell-dependent experimental liver injury in mice. Hepatology 30: 1441-1447.
49. Martuscelli G, Fiorellini JP, Crohin CC, Howell TH (2000) The effect of interleukin-11 on the progression of ligature-induced periodontal disease in the beagle dog. J Periodontol 71: 573-578.
50. Gemmell E, Seymour GJ (2004) Immunoregulatory control of Th1/Th2 cytokine profiles in periodontal disease. Periodontol 2000 35: 21-41.